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Abstract
Mounting evidence suggests that glycans, rather than merely serving as a “shield”, contrib-
ute critically to antigenicity of the HIV envelope (Env) glycoprotein, representing critical anti-
genic determinants for many broadly neutralizing antibodies (bNAbs). While many studies
have focused on defining the role of individual glycans or groups of proximal glycans in
bNAb binding, little is known about the effects of changes in the overall glycan landscape in
modulating antibody access and Env antigenicity. Here we developed a systems glycobiol-
ogy approach to reverse engineer the complexity of HIV glycan heterogeneity to guide anti-
genicity-based de novo glycoprotein design. bNAb binding was assessed against a panel of
94 recombinant gp120 monomers exhibiting defined glycan site occupancies. Using a
Bayesian machine learning algorithm, bNAb-specific glycan footprints were identified and
used to design antigens that selectively alter bNAb antigenicity as a proof-of concept. Our
approach provides a new design strategy to predictively modulate antigenicity via the alter-
ation of glycan topography, thereby focusing the humoral immune response on sites of viral
vulnerability for HIV.
Author summary
Carbohydrates on the HIV Env glycoprotein, previously often considered as a “shield”
permitting immune evasion, can themselves represent targets for broadly neutralizing
antibody (bNAb) recognition. Efforts to define the impact of individual glycans on bNAb
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recognition have clearly illustrated the critical nature of individual or groups of glycans on
bNAb binding. However, glycans represent half the mass of the HIV envelope glycopro-
tein, representing a lattice of interacting sugars that shape the topographical landscape
that alters antibody accessiblity to the underlying protein. However, whether alterations
in individual glycans alter the broader interactions among glycans, proximal and distal,
has not been heretofore rigorously examined, nor how this lattice may be actively ex-
ploited to improve antigenicity. To address this challenge, we describe here a systems gly-
cobiology approach to reverse engineer the complex relationship between bNAb binding
and glycan landscape effects on Env proteins spanning across various clades and tiers.
Glycan occupancy was interrogated across every potential N-glycan site in 94 recombi-
nant gp120 recombinant antigens. Sequences, glycan occupancy, as well as bNAb binding
profiles were integrated across each of the 94-atngeins to generate a machine learning
computational model enabling the identification of the glycan site determinants involved
in binding to any given bNAb. Moreover, this model was used to generate a panel of novel
gp120 variants with augmented selective bNAb binding profiles, further validating the
contributions of glycans in Env antigen design. Whether glycan-optimization will ad-
ditionally influence immunogenicity, particularly on emerging stabilized trimers, is
unknown, but this study provides a proof of concept for selectively and agnostically
exploiting both proximal and distal viral protein glycosylation in a principled manner to
improve target Ab binding profiles.
Introduction
Env glycoproteins on the surface of enveloped viruses, such as HIV [1–4], Dengue [5, 6], Ebola
[7], hepatitis C [8], influenza [9], Lassa [10], and Zika [6, 11], are the primary vaccine targets
for the induction of protective, broadly neutralizing antibodies (bNAbs). However, many of
these viruses evade the evolution and activity of bNAbs via sequence diversification and the
masking of critical Env epitopes by glycosylation. Various molecular engineering approaches
have been applied to generate HIV immunogens, such as stablizing a closed conformation of a
native like-trimeric Env [12–17] or creating minimal target sites of neutralizing vulnerability
on nanoparticluate structures [18]. These efforts have successfully elicited autologous neutral-
izing antibodies (Abs) in rabbits as well as in macaques [19, 20] and have been shown to guide
the first steps of germline bNAb precursor activation [21–26]. Unfortunately, these immuno-
gens have yet to prove sufficient for driving the evolution of broadly cross-neutralizing anti-
body (Ab) responses [24], indicating that new immunogen engineering strategies are urgently
required to improve antigenic profiles of Env immunogens for selective generation of Abs
against sites of neutralizing vulnerability.
Glycans represent more than half the mass of the HIV Env glycoprotein, obscuring nearly
the entire surface of the Env trimer. While these glycans were originally believed to shield
against an Ab response, over the past decade a number of bNAbs have been identified that
actively recognize these glycan themselves. Interestingly, these antibodies usually emerge fol-
lowing extensive evolutionary selection enabling them to generate unusual antigen-recogni-
tion domains (Fabs) that are able to reach through, and even utilize glycans, to access the
underlying protein surface [27–36]. Moreover, through high-resolution imaging approaches,
including cryo-electron microscopy (Cryo-EM), it is becoming apparent that bNAb:glycan
interactions are common across nearly all bNAb classes. Through linked viral evolution stud-
ies in subjects who evolve bNAbs, it is clear that while some glycans are essentially part of the
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Ab-epitope, other glycans actively block binding, thereby giving rise to a complex network of
potential agonists/antagonists [3, 4, 37, 38].
Antigenic opportunities for manipulating glycans on Env were first elucidated in studies
focused on either altering the overall glycans or certain glycans specifically [39–43]. These
approaches resulted in enhanced antigenicity, as well as the evolution of Abs to sites of neutral-
izing Ab vulnerability [44]. Removal of particular glycans in the C-terminus of the V2 loop
enabled the induction of neutralizing Abs with some breadth in non-human primates (NHPs)
[45, 46]. Similarly, the induction of autologous tier 2 neutralization following immunization
with native-like SOSIP trimeric Env was reproducibly attributable to induction of nAbs against
a “glycan hole” in the shield [47]. Elimination of the glycan located in loop D of the CD4-bind-
ing site resulted in enhanced germline B cell activation of VRC01 and NH45-46 precursors
[44, 48]. Moreover, recent reports point to the acquisition or loss of particular glycans in driv-
ing affinity maturation of specific bNAb lineages [49, 50]. However, while certain glycans may
help shape individual epitopes [30, 31, 33, 34, 36, 51], glycans interact with one another,
dynamically reshaping the exposed protein surface, coordinately influencing Ab binding
access [37, 52–56]. Collectively, these data all highlight the critical role of glycans, as individu-
als or as groups, contributing to the overall antigenic profile of the Env glycoprotein. Nonethe-
less, there remains inadequate understanding of systematic principles that could offer an
actionable path for the development of immunogens that can exploit the large mass of sugars
decorating viral protein surfaces.
While causal relationships between individual glycosylation sites, or groups thereof,
and bNAb binding have been defined [27, 30–36, 38, 44–46, 49–56], it is conceivable that
modulating glycan interactions more broadly may represent a further means to focus the
humoral immune response [57–59]. The Env glycans extend beyond the protein surface and
accordingly yield a topographical landscape of the macromolecule, influencing access to the
underlying protein. Changes in glycosylation at one site, such as addition or removal of a
particular glycan, may have a substantial impact on epitope availability even at relatively dis-
tal sites [37, 56]. Therefore, methods that can exploit both the protein and the glycans from a
multi-site, landscape perspective, may provide a benefit for improved HIV immunogen
design.
In this work we describe a multi-variate, combined experimental/computational glyco-
engineering strategy to rationally alter HIV envelope glycosylation with a goal of inducing
desirable topographical changes in epitope accessibility. First, a deconvolution model was con-
structed to reverse-engineer the data in a panel of 94 recombinant HIV Env antigenic profiles
screened against a battery of broadly neutralizing and non-neutralizing Abs. Glycan occu-
pancy at each n-linked glycan site (‘sequon’) was assessed by mass spectrometry, and both pro-
tein sequence and glycan occupancy were used as variables in the model to elucidate how Ab
binding is dependent on them. Next, based on this model, forward-engineering principles
aimed at changing the overall antigenic profile of any given HIV Env were ascertained. Using
a Bayesian machine learning algorithm permitted determination of key sequon sites that posi-
tively or negatively influence Ab binding. Finally, these results were then used in a de novo, in
silico protein antigen design model using an iterative antigenicity-guided sequence evolution
framework, seeking to predict alterations in the antigen that could selectively improve or
impair target antibody binding. These predictions were then used to synthesize novel antigens
that successfully bound to target bNAbs with enhanced and selective antigenicity. All together,
our work provides proof-of-concept, in an initial HIV Env application, for the advance of
multi-variate glycosite-based engineering of immunogens that can focus the humoral immune
response on sites of neutralizing vulnerability.
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Results
Site-specific glycan occupancy heterogeneity across HIV gp120 strains
Over the past decade, significant effort has been invested in the generation of stabilized, native,
trimeric HIV Env proteins or minimal scaffolds of sites targeted by bNAbs, aimed at focusing
the immune response to sites vulnerable to antibody mediated neutralization. While exciting
results continue to accrue, these proteins alone have not proven sufficient to drive neutralizing
Ab breadth. Strategies to further optimize the HIV Env glycoprotein for induction of bNAb
breadth thus continue to be urgently needed. Given our emerging appreciation for the anti-
genic nature of the large array of glycans that decorate the HIV Env glycoprotein, here we
hypothesized that the glycan shield itself might be strategically modified and exploited in a
rational manner, offering a potentially generalizable glyco-engineering approach that could be
applied to either trimeric or monomeric Env proteins. For proof-of-concept purposes, we
focused our study on a diverse panel of Env monomers.
Because of the remarkable sequence diversity among HIV viral variants, we assessed glycan
site occupancy across a panel of recombinant HIV Env monomers (gp120). Traditional assays
for HIV Env glycosylation have relied on enumeration of N-linked glycosylation sites (se-
quons; Asn-X-Ser/Thr, X 6¼ Pro), within a sequence (Figure A in S1 File). However, accumu-
lating data suggests that the presence of a sequon is necessary but not sufficient to guarantee
the presence of the associated glycan [60–64]. To address this discrepancy, we first conducted
a mass spectrometric N-linked glycoproteomic analysis of the glycan occupancy profiles for
each of 94 recombinant gp120 proteins that span clades A, B, and C with additional AE, AG,
and BC variants (Fig 1, Figure B in S1 File). Site-specific, N-linked glycan occupancy was
determined using proteolytic digestion, peptide deglycosylation, occupied site labeling, and
MS/MS fragment quantification and site-mapping. The glycan occupancy level was estimated
by calculating the ratio of the spectral counts of the glycosylated peptide in relation to the
overall incidence of the peptide, where the glycosylated peptide was quantified through 18O
isotopic labeling [65–67]. To validate linkage of the spectral count to the relative peptide abun-
dance, we tested spectral counting of a pre-mixed peptide population (Table A in S1 File); this
peptide mixture contained two nearly identical sequences: one with a particular sequon and
another with a Asn-to-Asp substitution within that sequon, to represent glycosylated and non-
glycosylated-peptide variants. The ratio of the spectral counts of the two peptides provided
consistent quantitation of the peptide relative distributions, giving confidence in this method.
From this N-glycoproteome analysis, 83% of the possible sequons across the panel of 94
gp120 variants were identified as quantitatively present, with 92% of the sequons exhibiting
full or partial occupancy (Table B in S1 File). The glycan occupancy profiles strikingly revealed
heterogeneity at nearly all sites (Fig 1A, S2 Table), and the likelihood of a site being occupied
was independent of its sequon frequency (Fig 1B and 1C, Figure C in S1 File). For example, for
some highly-conserved sequon sites (e.g., N156, N197, N241, N301) only moderate glycan
occupancy was observed, while other highly-conserved sequon sites demonstrated nearly com-
plete occupancy across the 94 proteins (e.g., N88, N234, N262).
Given the significant variation in viral sequences among the tested gp120s (Figure A in S1
File), the relationship between glycan occupancy and sequon sequence was evaluated to deter-
mine whether protein sequence alone could predict sequon occupancy. Classic sequons
(N-G-S/T) showed the highest degree of glycan occupancy, whereas N-E-S/T exhibited the
lowest glycan occupancy (Figure D in S1 File) and a number of sequons demonstrated inter-
mediate occupancy profiles. We also inspected glycan occupancy variance across all the sites
(Fig 1D) and mapped the sites with the top 15% highest variance into a Env trimer structure.
Interestingly, sites with high glycan occupancy variance were enriched within known bNAb
Glycan topography-based computational design of Env antigens
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epitopes (Fig 1E), except for the CD4 binding site epitope. This result indicates that the
observed heterogeneity over our 94 proteins is not simply related to unusual glycosylation on
monomeric gp120, but rather points to the possibility that HIV may actively exploit variation
in both protein sequence and glycan occupancy as a means to escape bNAb detection selec-
tively. In turn, sequons, with reproducibly variable glycosylation, provide an opportunity to
engineer glycoproteins.
Defining the glycan site occupancy relationships to bNAb binding
Previous efforts to define the role of glycan occupancy in shaping antibody activity have focused
largely on the impact of removing or adding one or a few glycans. We continued our multi-vari-
ate approach by using ELISA to interrogate the impact of glycans on Ab binding, for 13 bNAbs
and 3 non-NAbs (F105, A32, 447-52D) (Figure E in S1 File) against the 94 gp120s for which gly-
can occupancy profiling was obtained (Fig 1A). These Abs covered four well-defined epitope
clusters: N332 & V3 glycan (PGT121–128), N332 & outer domain glycan (PGT135-136, 2G12),
V3 loop (447-52D), and CD4 binding site-like (VRC01, B12, F105, A32) [12, 68]. While all Abs
bound to clade B variants more effectively, the various Abs demonstrated unique binding pro-
files across clade A and C and recombinant variants (Fig 2A). Despite the observed binding pro-
file heterogeneity, clusters of binding profiles were observed across the proteins, pointing to
clear epitope families, with clusters of binding including PGT125–128, PGT121–124, PGT135–
136, and the CD4 binding site–targeting Abs (B12, VRC01, F105, A32). Thus, related-monoclo-
nals bound preferentially to similar sets of gp120s, as expected based on epitope availability of
target epitopes on particular gp120 structures (Fig 2B).
Based on the disparate Ab binding profiles (Fig 2A) and the known glycan occupancy dif-
ferences (Fig 1A), we ascertained the impact of glycan site occupancy on Ab binding. The cor-
relation matrix, which depicts the pair-wise covariance between glycan site occupancy and Ab
binding across the gp120 panel, illustrates a strong relationship between glycan occupancy and
Ab binding profiles (Fig 2C). A striking bimodal pattern was observed, where glycan occu-
pancy at specific sites either agonized or antagonized Ab binding. Moreover, intriguing com-
plex patterns also emerged from these data, including the observation of “super antagonist”
sites (e.g., N149 and N139) and “super agonist” sites (e.g., N332 and N362; Fig 2C, highlighted
in black squares) that affected binding of all tested Abs, potentially acting through glycoprotein
stability rather than direct antigenicity. Additionally, sites exhibiting epitope-specific modula-
tory effects were found (Fig 2C, highlighted in red/green/pink squares). Notably, while the
N332 is known for its critical role in shaping V3-family binding, it is not known for its role in
shaping other bNAb responses. However, the data here suggest that the N332 glycan plays a
much broader role in bNAb binding, including shaping the epitope of all CD4–binding site
Abs. This observation indicates that proximal as well as distal glycans can contribute to antige-
nicity, potentially via alterations in the topographical remodeling of the overall glycan shield.
Thus, groups of both positively-influencing and negatively-influencing glycans were associated
Fig 1. Global glycan occupancy site utilization across 94 HIV gp120s. (a) The heat map represents the N-linked glycosylation site occupancy
profiles of 94 distinct recombinant gp120 proteins. Site utilization was determined by mass spectrometry, and the frequency of utilized sites at each
potential glycosylation site (columns) is presented using a yellow-to-black gradient. The gray boxes depict the absence of a sequon (N-X-S/T, X6¼P) at
that specific site within that sequence. The right panel shows the average glycosylation site occupancy per protein. N-glycan sites were aligned based
on the HXB2 sequence. Canonical N-glycan sites were designated based on the aligned sequence. Non-canonical N-glycan sites, which are not
present in the HXB2 sequence, are shown in decimal numbers, based on the previously aligned N-glycan site. (b)-(e) The bar graphs show (b) the
frequency of sequons present at each potential N-glycan site across all strains; (c) the mean (± standard deviation) glycan occupancy; (d) the variance
of the glycosylation site occupancy (dotted line represents the top 15th percentile). (e) The N-glycan sites with the top 15% highest variance were
mapped onto the BG505.SOSIP crystal structure (PDB #: 4NCO) highlighted as red. The approximate binding epitopes of various bNAbs on the Env
structure are labeled in hatched circles.
https://doi.org/10.1371/journal.pcbi.1006093.g001
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with individual classes of Abs, pointing to glycans that either selectively decrease binding to
non-NAbs (red boxes) along with glycans that either increase or decrease binding to target
bNAbs (PGT121 and PGT128 –in green and pink, respectively). These data provide new
insights into the directional influence (i.e., agonistic or antagonistic) of individual glycans as
well as clusters of glycans in shaping Ab binding to HIV gp120.
Defining rules that govern the impact of glycan occupancy on bNAb
binding using Bayesian machine learning
To more rigorously model the integrative contribution of proximal and distal glycans in collec-
tively shaping Ab binding profiles, and to define the minimal glycans required to shape the
overall glycoprotein topology, we developed a supervised Bayesian machine-learning algo-
rithm to capture relationships—linear as well as non-linear—between site occupancy profiles
and Ab binding fingerprints. This computational framework consisted of two key parts. First,
a support vector regression (SVR) model [69] involving incorporated kernels, to uncover rela-
tionships between glycan sites (individually and in combination) and Ab binding. And, sec-
ond, a Bayesian Markov Chain Monte Carlo (MCMC) sampler [70, 71], to approximate how
the various sites and combinations of glycans impact binding and ultimately capture the mini-
mal set of optimal glycan sites that predict binding.
As a proof of concept, we applied this approach to defining the minimal combination of
glycan predictors for PGT121 binding. We built models based on 4 different types of input var-
iables: sequons alone (Figure A in S1 File); protein sequences alone; glycan occupancies alone
(Fig 1A); protein sequences and glycan occupancies inputs. 10-fold cross-validation was per-
formed for each model to test robustness and prediction accuracy. The models based on
sequons or sequences alone were correlated relatively poorly to the experimental ELISA bind-
ing results, with r = 0.53 and 0.75, respectively (Fig 3A and 3B). The model based on glycan
occupancy alone was better correlated with binding activity (r = 0.81, p< 0.001; Fig 3C), sug-
gesting that glycan occupancy was more predictive that sequence alone in predicting antibody
binding. However, the fourth model, combining both glycan occupancy and protein sequence,
showed the best performance with robust predictive power (r = 0.94, p< 0.001) and a very low
MSE (0.17) (Fig 3D), confirming that combination of glycan occupancy and sequence infor-
mation can substantively account for the complex interaction between Abs and Env proteins.
Given the superior improvement in model performance when both glycan occupancy and
sequence were included, we next constructed models for additional Abs, incorporating direc-
tionality of glycan on antibody binding (i.e., positive or negative influence on binding) to
deconvolute and define the specific glycosylation sites (Fig 3E and Figure F in S1 File,
q< 0.01) and amino acid residues (S3 Table) that most strongly contribute to binding. Hierar-
chical clustering consistently showed that Abs recognizing related epitopes share similar gly-
can-utilization profiles (Fig 3E). Glycans previously appreciated to be involved in shaping
antibody binding, including N332, were clearly found to be important across all the PGT Abs
Fig 2. Relationship between glycosylation site occupancy and Ab binding fingerprints. (a) The heat map represents the bNAb- and non-NAb
binding profiles for 16 Abs (columns) against a panel of 94 recombinant gp120 glycoprotein variants (rows). The ELISA binding activity was
determined by the OD value of the protein concentration = 80 ng/ml based on the protein titration curve (Figure E in S1 File). (b) The
correlation matrix illustrates similarities and disparities in the Ab-binding (dark purple = highly correlated; white = non-correlated). Families of
bNAbs with more similar glycan footprints cluster along the y-axis or x-axis, depicted by the color blocks. (c) The correlation matrix depicts the
relationship between individual Ab binding profiles (columns) and glycosylation site occupancy at individual N-glycan sites (rows) across the
gp120 variants. The heat map is color-coded based on the strength and directionality of the correlation coefficient, where antagonistic sites
(those decreasing binding affinity) are depicted in blue and agonistic sites (those increasing binding affinity) are depicted in red. The glycan sites
defined as “super antagonists/agonists”, which affect binding by all Abs, are highlighted in black squares, and the sites that exhibit epitope-
specific modulation against different Ab clusters are highlighted in red, pink, or green squares.
https://doi.org/10.1371/journal.pcbi.1006093.g002
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along with 2G12, but were not among the most critical predictors of binding for models for
the CD4bs-dependent Abs. Importantly, critical glycans for all Abs were observed across the
entire protein sequence, indicating that glycans proximal as well as distal to the Ab binding
site contribute to Ab binding profiles. Nonetheless, it must be considered that our models,
based on the limited 94-monomer dataset, may not completely rule out additional sites.
To gain deeper understanding of how proximal and distal glycans influence Ab binding, the
linear glycan sites and protein residues were projected onto a 3-dimensional structure of gp120
(Fig 3F, Figure G in S1 File). Using PGT121, PGT128, and VRC01 as examples, both positively-
influencing and negatively-influencing glycan sites were found within the PGT121/128 binding
site but not within the VRC01 binding site, as expected. However, both categories of glycan
sites were also observed outside the immediate Ab binding region for all Abs. Interestingly, crit-
ical protein residues defined by the model were located both within and outside the VRC01 epi-
tope but were largely scattered outside the PGT121/128 binding sites. These findings highlight
broad distribution of influential glycans and amino acids across the surface of the HIV Env pro-
tein beyond those within the Ab binding site itself; we imagine that this influence likely tran-
spires through alterations in the overall topography of the viral protein surface.
Finally, projection of PGT122-specific glycan and amino acid determinants on the co-crys-
tal structure of the PGT122 Fab and BG505 SOSIP gp140 Env trimer [4] further illustrates how
these sites coordinately impact Ab binding (Fig 3G). Sites facilitating PGT122 recognition
comprised glycans that participate directly in Ab binding (N332 and N295), proximal glycans
located on the nearby V1/V2 loops (N130, N138, N143/147 and N188), and distal glycans
located on the outer domain of gp120 (N262, N362, N401, N410 and N462) that may reduce
conformational flexibility of glycan clustering and maintain epitope accessibility [37, 53]. Con-
versely, antagonistic glycan sites were mostly located immediately around the binding site
(N139/141, N149, N186/187, N334 and N407/408). This arrangement could reshape protein
topography to limit epitope access or increase local steric hindrance preventing further glycan
processing into the correct glycan structures [53], in either case interfering with PGT122 bind-
ing. Additionally, key amino acid determinant, residue 323, was identified within the epitope
[4], whereas others were scattered across the protein, highlighting both the proximal and distal
influence of both glycans and amino acid changes in shaping the protein surface. Thus, as the
majority of crystal structure studies have focused mainly on proximal glycans that contribute
directly to Ab access, the importance of distal inhibitory or agonizing glycans may also be
exploited to optimize immunogen design.
Using topography oriented rational design to develop antigenically
enhanced gp120 glycoproteins
With an appreciation for the contribution of both proximal and distal glycans in shaping Ab
binding, we hypothesized that glycan occupancy signatures could be exploited to guide the
Fig 3. Defining the glycosylation site determinants that shape bNAb binding profiles. (a)-(d) Four different Bayesian MCMC-SVR models were
evaluated for their respective abilities to predict PGT121 binding to the 94 proteins. The models include a Bayesian MCMC-SVR model based on: (a)
sequon presence (Figure A in S1 File); (b) protein sequence; (c) glycosylation site occupancy; or (d) glycosylation site occupancy and sequence
combined. Cross validation (100-iterative 10-fold) was used to evaluate model performance. Goodness-of-fit was assessed and is reported as the mean
squared error (MSE) between predicted and ELISA-measured binding. (e) Heat map shows the binding signatures of individual Abs (rows), where the
selected glycan sites (determinants) that mediate effects on Ab binding are highlighted. NAbs that share similar glycan determinants are grouped by
hierarchical clustering. (f) The significant glycan site determinants for PGT121, PGT128, and VRC01 are plotted onto a 3-dimensional gp120 monomer
structure using the same directional color coding as the heat-map. Additionally, the critical protein residues predicted by our model are shaded in
yellow on the same 3D structure. Finally, broad Ab-binding sites were highlighted for each bNAb in hatched circles. (g) Agonistic and antagonistic
glycan site determinants and critical protein residues for PGT122 are projected on the BG505 SOSIP.664-PGT122 co-crystal structure (PDB #: 4NCO)
with the same color coding. The V3 loop is highlighted in light green shading.
https://doi.org/10.1371/journal.pcbi.1006093.g003
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design of gp120 proteins with improved binding properties for specific bNAbs. We employed
an optimization algorithm for this purpose, based on dynamic evolution based on glycan occu-
pancy, using the same Bayesian machine learning core as above. This algorithm iteratively
evolved a given gp120 sequence in silico by perturbing defined individual glycan sites (mutat-
ing one glycan site at a time), aimed at driving enhanced or impaired bNAb binding for a
given bNAb (Fig 4A). This serial computational mutagenesis approach sampled the antigenic-
ity landscape of any given combination of glycan occupancy profiles, ultimately generating a
particular combination of glycans that could enhance or impair target bNAb binding most
effectively. During iterative glycan site perturbations, the model assumes that the changes (e.g.,
knock-in or knock-out) of target sites do not influence glycan occupancy of other sites. This
approach was applied with the goal of generating immunogens optimized for PGT121 and/or
PGT128 binding, due to their related but distinct antigenic fingerprint profiles (Fig 2A). The
clade A MF535.W0M.ENV.D11 gp120 sequence was used as a starting sequence, because of its
negligible binding profile to both bNAbs (Fig 2A, Figure E in S1 File).
Antigens were first designed to exhibit enhanced binding to one of these two bNAbs, based
on the addition of bNAb-specific agonistic glycan sites and removal of bNAb-specific antago-
nistic glycan sites (Fig 4B and 4C, +PGT121 and +PGT128). The engineered proteins were
expressed (Figure H in S1 File) and proper folding was verified based on binding by VRC01
(Figure I in S1 File). In successful validation of our model predictions, both antigens exhibited
enhanced binding to their respective bNAb: PGT128 binding was enhanced to the +PGT128
antigen, and PGT121 binding was enhanced to the +PGT121 antigen (Fig 4D and Figure I in
S1 File). We also engineering a third antigen, with the goal of concomitantly optimizing glyco-
sylation to enhance binding to both PGT121 and PGT128 bNAbs (Fig 4B and 4C, +PGT121+
PGT128). The resulting +PGT121+PGT128 antigen showed significant enhancement of bind-
ing activity (12-fold increase) to both bNAbs (Fig 4D). These results argue that our antigen
design approach based on the addition or removal of both distal and proximal agonistic or
antagonist glycans, aimed at remodeling the overall topography of HIV Env antigens, can
effectively improve antigenicity.
As a yet further design challenge, we tested whether glycan engineering could selectively
shift antigenicity between bNAbs–facilitating access to one particular bNAb while occluding
another. Toward this aim, we designed antigens predicted to enhance PGT121 binding while
inhibiting PGT128 binding or vice versa (Fig 4B and 4C, +PGT121-PGT128 or -PGT121+
PGT128), despite the propinquity of the PGT121 and PGT128 epitopes. As an example for the
+PGT121-PGT128 antigen, PGT128-specific antagonists such as N442 were added while
PGT128-specific agonist glycan sites such as N140 were removed or kept absent. Because several
glycan sites exist that impair binding of both bNAbs, decisions about which sites to include
were dictated by the quantitative degree of a specific glycan contribution to individual bNAb
binding models. For instance, N139 had a negative influence on binding for both PGT121 and
PGT128, but this effect was stronger for PGT121 than PGT128 (Fig 4B, top panel); accordingly,
N139 was incorporated into the -PGT121+PGT128 antigen. The–PGT121+PGT128 antigen in
fact demonstrated selective binding to PGT121 and PGT128, to levels even higher than pre-
dicted; however, selective binding was not observed for the +PGT121-PGT128 antigen. While
the algorithm successfully generated an antigen that was selectively recognized by PGT128, we
sought to understand why the antigen predicted to be PGT121-selective failed (Fig 4D).
Closer inspection of the glycan sites in +PGT121-PGT128 showed that a cluster of tightly
packed glycans (N339, N355, N362, N363, N392, N396 N398) were chosen by the model, and
we recognized that these could have adverse effects on PGT121 binding. To test the corollary
hypothesis, then, that these new glycans may have created glycan clusters that sterically hin-
dered Ab binding or unstabilized gp120 conformation (Figure J in S1 File), we estimated their
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steric effects using glycan-glycan auto-correlations based on occupancy profiles. Relative to
the total degree of steric hindrance observed for the MF535.W0M.ENV.D11 gp120 sequence,
which was approximately 1 (Fig 4E), the overall degree of glycan steric effects across all 94
gp120s was relatively similar and homogenous across all sequences (Fig 4E, pink region). This
level of steric effects between glycans likely reflects a natural fitness landscape of the gp120 gly-
can density profiles that are naturally accommodated across clades and tiers of viruses. Simi-
larly, glycan steric effects of the novel antigens, other than the +PGT121-PGT128 antigen,
were close to those observed for the panel of gp120 proteins. On the other hand, the degree of
steric hindrance observed for the +PGT121-PGT128 construct was significantly higher than
all other antigens—nearly three times the degree of steric hindrance observed for the original
MF535.W0M.ENV.D11 sequence (Fig 4E). Thus balancing steric effects, in addition to opti-
mizing individual glycans, likely offers the optimal approach to modulate antigenicity.
Based on this new insight, we designed the +PGT121-PGT128 antigen taking into consider-
ation the mutual steric effects of glycans as an additional design principle. Reducing glycan
steric hindrance while preserving the glycan that could concomitantly agonize PGT121 antag-
onize PGT128, a new +PGT121-PGT128 2nd was generated. This novel antigen readily bound
PGT121 and was not recognized by PGT128 (Fig 4D), in a manner demonstrating good con-
sistency between model predictions and experimental measurements (r = 0.78 in PGT121
binding; r = 0.90 in PGT128 binding prediction, Figure K in S1 File), further validating our
modeling approach. More broadly, these results suggest that an expanded analysis of the gly-
can occupancy profiles of a larger number of non-neutralizing and neutralizing Abs, against
not only gp120 but also gp140 and the emerging native-like trimers, could prove beneficial for
designing antigens yielding enhanced antigenicity to drive specific desired bNAbs.
Discussion
With the growing appreciation for the participation of glycans in bNAb binding and the strik-
ing effects observed with the removal or addition of individual or groups of proximal glycans
[39–45, 48], new antigen design approaches able to exploit these post-translational structures
could offer a powerful avenue to improve development of therapeutically effective antigens.
Our study aimed to develop a systems glycobiology approach to exploit glycosylation to
enhance antigenicity, by integrating global site-specific glycan occupancy, peptide sequence,
and Ab binding fingerprints to a panel of 94 distinct HIV envelope monomers, using compu-
tational modeling to predict engineered antigens optimized for desired binding characteristics.
Our findings demonstrate an extensive heterogeneity in glycan occupancy profiles across 94
distinct HIV Env gp120s, dictated by unique sequons, which together define glycans that
shape Ab binding. In addition, glycan mapping across these Env antigens raised a previously
underappreciated role of both proximal and distal glycans together, distributed in 3D
Fig 4. Proof-of-concept glycoengineering of gp120 antigens to selectively enhance antigenicity. (a) Cartoon depicts the overall de novo antigen optimization
design approach. (b) The heat maps, as in Fig 3E, depict the glycosylation site determinant profiles preferred by PGT121 and PGT128 including directional
glycan coloring across all N-glycan sites (columns). (c) The top heat map represents the original wild-type MG535.W0M.ENV.D11 gp120 sequon site profile
(yellow = sequon site absent and black = sequon site present); middle and bottom heat maps indicated the introduced point mutations (brown = sequon site
knock-in, light blue = sequon site knock-out) for the gp120s engineered to have increased binding to PGT121 (+PGT121), PGT128 (+PGT128), and both
PGT121 and PGT128 (+PGT121+PGT128); also, the gp120s engineered to selectively bind PGT121 but not PGT128 (+PGT121-PGT128), or PGT128 but not
PGT121 (-PGT121+PGT128 and -PGT121+PGT128 2nd). (d) The bar graph depicts comparison of the predicted binding (beige = PGT121 and
brown = PGT128) and ELISA-determined binding (light blue = PGT121, dark blue = PGT128, and grey = VRC01 binding) to the wildtype and engineered
gp120s. ELISA binding activity was determined as in Fig 2A. In order to compare the model predictions to the experimental results, both the model and actual
ELISA values were normalized to wild-type binding values, which were set to 1. Error bars indicate the standard deviation from six replicates. (e) The bar graph
shows the degree of steric hindrance found on each antigen by summing all steric glycan site pairs (Figure J in S1 File), if any site in the pair was considered
essential for predicting Ab binding. Pink highlighted region denotes the average and range of the degree of steric hindrance across all the 94 recombinant gp120
proteins.
https://doi.org/10.1371/journal.pcbi.1006093.g004
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structures over the glycan surface, that govern Ab binding by potentially shaping the overall
surface of the glycoprotein in manner that may alter epitope exposure and access. Moreover,
this information was then used to build a computational antigen design algorithm, aimed at
optimizing glycan occupancy profiles for desired antigenicity. Engineered antigens success-
fully enhanced binding to target bNAbs, and even were able to selectively skew antigenicity to
discriminate between bNAbs that target overlapping regions of the viral envelope. These pre-
dictions were successfully validated by dedicated tests of a number of experimentally produced
antigens with respect to binding properties across the set of targeted bNAbs. Of course,
whether antigenicity represented by Ab binding will translate to enhanced immunogenicity
[12, 19], and whether this approach more generally will apply to native Env trimers or other
viral antigens, is uncertain. Nonetheless, our study provides proof of concept that a surface gly-
coprotein glycan shield can be engineered in a rationale, computation-based manner, to
improve target Ab binding profiles.
Analyses of glycan site occupancy on two Env trimers, the BG505 SOSIP.664 [12] and
Clade C CZA97.012 [13] trimers (Figure L a-b in S1 File), has pointed to higher overall occu-
pancy on trimeric forms of Env [13, 37, 72, 73] compared to the various monomer sequences
examined in this study. However, among these monomers occupancy varied from 63–97%
(Fig 1A, right panel), where some sequences exhibited occupancy profiles similar to previously
analyzed native trimers, linked to the inclusion of specific high occupancy sequons that also
exist within previously studied trimeric antigens. As occupancy is controlled co-translationally
and post-translationally [74], differences observed on trimers as well as monomers are likely
not only related to misfolding or mis-processing of the proteins but also, critically, to sequence
variation (Figure D in S1 File), local secondary structure, as well as surface geometry around
the sequons that may all contribute to determining whether Oligosaccharyltransferase (OST)
can access a glycosylation site [75]. Moreover, that the highest degree of occupancy variation is
observed at N-glycan sites critical for bNAb binding, further argues that the observed variation
is not due to aberrations in glycosylation of monomers, but related to evolutionary selection of
variability at key sites of viral vulnerability. However, beyond occupancy differences, that are
likely less divergent between monomeric and trimeric protein structure, the composition of
the glycan may be more highly influenced by quaternary structures due to enzyme accessibility
issues. Thus, while only a limited number of trimers have been analyzed for glycan occupancy
thus far, with restricted clade and neutralization tier coverage, future analysis of larger num-
bers of trimers may provide critical insights into the opportunities to glycoengineer more
native-like molecules along the lines of our approach.
Protein engineering strategies aimed at generating soluble native-like Env trimers, such as
stablilzing the gp120:gp41 interaction [12–15], fixing the epitopes in a closed conformation
[16, 17], and optimizing combinations of different trimer variant sequences [76] have been
proposed to either target bNAb precursors [21–23] or induce Abs with cross-reactive breadth
[19, 20]. We elected here to use a panel of 94 distinct gp120 monomers, due to the breadth of
sequences that could be selectively analyzed, to exploit both sequence and glycan diversity in
our glycan engineering efforts. Importantly, while nearly all sequons are reproducibly occu-
pied on the SOSIP.BG505 immunogen similar to the previous report [73] (Figure L c in S1
File), preliminary analyses of additional native-like trimers suggest increased variability in gly-
can occupancy (Figure L a in S1 File), driven by diverging sequons. Despite these differences,
the use of a library of monomeric antigens possessing sequence as well as glycan occupancy
heterogeneity, gave us a unique opportunity to develop a robust model interrogating the role
of individual glycans and sequences in tuning Ab binding profiles. This data set afforded the
discovery of novel sequons that can be exploited to control levels of glycan occupancy in the
future for HIV and other therapeutic proteins. Moreover, results from our study pointed to a
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role for distal glycans in shaping Ab binding profiles, emphasizing the need to include infor-
mation outside of an Ab-binding footprint to develop antigenically enhanced antigens. Given
that the glycan shield covers the majority of the Env surface, our glycan engineering approach
may provide a novel strategy for vaccine development efforts via the modulation of overall
antigen topography to selectively mask immunodominant, and potentially distracting, epi-
topes, while improving the targeted induction of bNAbs through the creation of targeted “gly-
can holes” that enable vulnerable site recognition [20, 47]. Additionally, because inter-
protomeric glycan:glycan interactions have been observed in the trimeric structure [37, 77], it
may be additionally possible to optimize trimer stability or even adapt antigenicity fingerprint-
ing to screen for improvements in germline-reverted B cell receptor recognition to prime
immunity more effectively [44, 78].
The MF535.W0M.ENV.D11 gp120 sequence was selected as an initial point for our gly-
coengineering approach (Fig 4B). While this wildtype gp120 contains N137, N156, and N301,
other critical glycans for PGT121 and PGT1218-binding (N295 and N332) are missing [35, 52,
54, 79]. Thus this sequence was optimal for engineering, given its negligible binding to both
bNAbs (Fig 2A, Figure E in S1 File). We designed our optimized gp120 proteins using a
computational design algorithm in which the selected mutations were focused on the glycan
site determinants for both PGT121 and PGT128, including proximal and distal sites (Fig 4B).
While some N-glycans, such as the addition of N295 and N332, likely have more profound
effects on improving PGT121 and PGT128 binding, addition and removal of other glycans,
that were both proximal and distal, also modulated overall as well as selective bNAb binding.
Our computational design model involved a hybrid framework combining machine learn-
ing algorithms (support vector machine, SVM) with a Bayesian MCMC sampler. Advantages
of integrating these two algorithms were multiple: the SVM implemented kernels capturing
mutual dependencies among multiple variants (glycans and protein residues); the Bayesian
MCMC sampler reduced computing time and mathematically ensured the identification of the
optimal solutions in a high-dimensional feature space; the probabilistic machine learning
model then dealt with uncertainties of measurements from high-throughput assays (N-glyco-
proteome analysis, ELISA-based Ab binding), reducing model overfitting of noisy data; and,
the flexible machine leaning enabled the incorporation of additional sequence, glycan struc-
ture, neutralization profiles, and affinity measurements, that ultimately led to the generation of
a robust model. Future efforts aimed at designing next-generation glyco-engineered immu-
nogens may benefit from a number of further advances including (but not limited to): the
incorporation of glycan occupancy data from a larger number of Env proteins (including
monomers, trimers, and native-like structures); the inclusion of the glycan structure data itself
(e.g., oligo-mannose, hybrid, complex); the addition of binding profiles from a larger reper-
toire of Abs (including both broadly neutralizing and non-neutralizing Abs), germline binding
profiles, measures of binding affinity/avidity; the inclusion of virus:BCR evolutionary dynam-
ics to help the algorithm learn to evolve envelope intermediates; and, the final consideration of
occupancy profiles from envelopes on the surface of the virus or the cell, that may adopt dis-
tinct conformations.
Given the enormous evolutionary landscape explored by HIV, and the fact that carbohy-
drates represent half the mass and most of the surface of the viral envelope, our study points to
the importance of exploring both glycan occupancy and sequence diversity for optimal antigen
design. In the future, our approach may be extended to address profiles associated with
enhanced germline BCR binding or intermediate BCR ancestor interactions, ultimately aimed
at designing sequential immunization strategies or “multi-valent vaccines” able to elicit multi-
ple lineages of bNAbs from a single “super immunogen”. Ultimately, we believe that our work
raises promising prospects for topographically designed optimized glycoproteins not only
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through protein engineering but also through the remodeling of the glycoprotein glycome,
which in concert may maximally enhance immunogen antigenicity.
Materials and methods
HIV gp120 variant proteins and broadly neutralizing Abs
100 recombinant Gp120 protein monomers were purchased from Immune Technologies.
Purity, protein quality, and testing were performed on recombinant antigens by Immune
Technology Corp. Proteins were purified from 293 culture supernatants using nickel columns,
and purity was assessed by SDS page by Immune Technology Inc. Additionally, we performed
a second SDS-PAGE (Figure B in S1 File) upon receipt of these proteins to ensure that only
high-quality, antigens were used for ELISAs and Mass Spectrometry. FPLC was performed on
a subset of proteins to spot-check protein quality. New batches of proteins were acquired from
Immune Technology if more than 1 band was observed on the SDS-page. Proteins that exhib-
ited more than 1 band across 2 batches were eliminated from consideration, resulting in the
final inclusion of only 94 recombinant gp120 monomers in the analysis (S3 Table). PGT121,
A32, F105, 447-52D and VRC01 Abs were obtained from the NIH AIDS reagents program.
2G12 and B12 Abs were purchased from Polymun Scientific. PGT122, 123, 124, 125, 126, 127,
128, 135 and 136 were generously provided by Dr Dennis Burton (Scripps Research Institute).
ELISA-based antigenicity assay
ELISA assays were performed by capturing gp120 monomers on D7324-coated (anti–C-termi-
nal gp120 sheep Ab, Aalto Bioreagents) plates, to directionally and consistently position the
recombinant proteins for antibody binding. Nunc Maxisorp 384-well plates were coated over-
night at 4˚C with 10 μg/ml of D7324 in 0.1M NaHCO3 (pH 8.6). Plates were washed 4 times
with PBST (PBS ±0.01% tween) and blocked with PBSA (PBS containing 5% BSA) for 1 hour
at room temperature. After 4 washes with PBST gp120 proteins were added at 80 ng/ml final
concentration in PBSA (optimal protein concentration for ELISA was evaluated by protein
titration assays based on 6 selected proteins from different clades, Figure E in S1 File) and
incubated for 2 hours at room temperature. After washing 6 times with PBST, bNAbs were
added at 10 μg/ml in assay diluent (PBS containing 5% BSA and 20% sheep serum) and incu-
bated for 2 hours at room temperature. Following 6 washes in PBST, biotin-conjugated mouse
anti-human IgG (BD Biosciences) was added to each well at 1:1000 dilution in PBSA and plates
were incubated for 1 hour at room temperature. After 6 washes in PBST, high-sensitivity strep-
tavidin-HRP (Pierce) was added to each well at 1:100 dilution in PBSA and incubated for 1
hour at room temperature. Plates were washed 6 times in PBST and developed by adding
UltraTMB substrate (Pierce) to each well. Development was stopped by adding 2M sulfuric
acid and plates read at OD450 with Tecan 1000 pro reader. Background OD values (wells
without gp120) were subtracted from test wells containing gp120 proteins. Two biological
replicates and three technical replicates for each bNAb were performed to provide statistical
estimation and evaluate assay reproducibility. ELISA data from biological replicates were
normalized by median centering to avoid systematic variance, aiding in cross-experiments
comparison. Reproducibility between replicate data sets was evaluated by examining the coef-
ficients of variation (CV).
Identification of sequons within HIV gp120 sequences
94 HIV gp120 sequences were multiply aligned by Clustal Omega (EMBL-EBI), based on the
curated alignments HMM model from Los Alamos HIV database [80]. The consensus sequons
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(N-X-S/T) were identified in each aligned sequence to identify all potential glycosylation sites.
The position number of individual sequons for each aligned sequence was mapped back to the
HXB2 sequence. Nomenclature for the positions of the sequons not aligned to HXB2 was
determined by the previously aligned position present within HXB2; for instance, N137.5 indi-
cates the glycosylation site found at the fifth residue after Position 137 in HXB2.
Defining glycan occupancy by mass spectrometry
5 μg of each gp120 protein (Immune Technology Corp.) was denatured by incubating with 10
mM of dithiothreitol at 56˚C for an hour and alkylated by 55 mM of iodoacetamide for 45
minutes in the dark prior to digestion with proteases (Promega) at 37˚C overnight. Various
combinations of proteases were used for different samples depending on their particular pro-
tein sequences to achieve optimal detection of potential glycosylation sites. The resulting gly-
copeptides were deglycosylated by incubating with PNGaseF (ProZyme) in the presence of
H2
18O water (Cambridge Isotope Laboratories) overnight. The deglycosylated peptides were
then dried and reconstituted in 0.1% formic acid. Deamidation of any Asn would result in a
mass shift of +1. We purposely controlled for mapping of N-linked sites by performing only
the enzymatic deglycosylation in the presence of O18-water so as to generate a mass shift of
+3. Following deglycosylation, the sample was immediately removed from O18-water and
replaced with non-isotope heavy buffers. We also performed the deglycosylation below pH7
since basic conditions promote deamidation [81]. Finally, when database searching, we
allowed for Asn +1 and +3 for all Asn but only observed Asn +3 residues in consensus sequons
further suggesting the lack of deamidation. In addition to Asn +1 (deamidation) and Asn +3
(deglycosylation), we also allowed for oxidation of methionine and alkylation of cysteine resi-
dues. Peptides were separated on a 75 μm (I.D.) x 15 cm C18 capillary column (packed in
house, YMC GEL ODS-AQ120A˚
´
S-5, Waters) and eluted into the nano-electrospray ion source
of an Orbitrap Fusion Tribrid mass spectrometer (Thermo Fisher Scientific) with a 180-min
linear gradient consisting of 0.5–100% solvent B over 150 min at a flow rate of 200 nL/min.
The spray voltage was set to 2.2 kV and the temperature of the heated capillary was set to
280˚C. Full MS scans were acquired from m/z 300 to 2000 at 120k resolution, and MS2 scans
following collision-induced fragmentation were collected in the ion trap for the most intense
ions in the Top-Speed mode within a 3-sec cycle using Fusion instrument software (v1.0,
Thermo Fisher Scientific). A protein database was compiled from 94 gp120 protein sequences
provided by Immune Technology Corporation. Raw spectra were searched against the gp120
protein database using SEQUEST (Proteome Discoverer 1.4, Thermo Fisher Scientific) with
full MS peptide tolerance of 20 ppm and MS2 peptide fragment tolerance of 0.5 Da, and fil-
tered using ProteoIQ (v2.7, Premier Biosoft) at the protein level to generate a 1% false discov-
ery rate for protein assignments. Glycan occupancy Gai of a potential glycosylation sequon ai
was determined as follows,
Gai ¼
X
POccupiX
POccupi þ
X
PUnoccupj
ð1Þ
G represents a ratio of total spectral counts (generated by ProteoIQ) between the 18O-labeled
peptides POccupi containing the glycosylated sequon ai and all detected peptides containing the
sequon ai with glycosylated POccupi or unglycosylated PUnoccupi forms. The glycan occupancy
threshold for ai was set as sum of POccupi and PUnoccupi > 10 to avoid instrumental noise at low
spectral signal. Occupancy of peptides with multiple sequons was determined by analyzing the
ratio of the fragments in MS/MS that in most cases lead to specific quantitative assignment of
Glycan topography-based computational design of Env antigens
PLOS Computational Biology | https://doi.org/10.1371/journal.pcbi.1006093 April 20, 2018 17 / 28
glycosylated sequons; in a limited set of cases where Asn residues were adjacent or 3 AAs apart
and not able to be accurately separated for quantification by multiple unique MS/MS frag-
ments, the sequons were considered to be equally occupied.
Pairwise covariance analysis between glycan occupancy and antigenicity
To quantitatively assess direct relationships between site-specific glycosylation occupancy and
Ab binding, a matrix of values for pairwise Pearson correlations between site occupancy and
Ab ELISA binding profiles was constructed. A given correlation coefficient characterizes the
strength of the relationship between occupancy levels at individual sites and Ab binding; the
sign of the value informs whether glycan presence at that specific site has positive or negative
influence on binding.
Bayesian machine learning algorithm for identifying glycan sites critical
for Ab binding
bNAb binding to the HIV envelope usually involves multiple glycans, often located proximal
to an epitope. However, distal glycans may also contribute through conformational changes to
the envelope. Thus, to define global glycan site combinations concomitantly important for Ab
binding, we developed an algorithm that integrated two computational methods. First, a sup-
port vector regression (SVR) algorithm that implements support vector machines (SVMs) [69]
was employed as a supervised learning model to predict Ab binding activities based on glycan
site occupancy values. Second, a Bayesian Markov Chain Monte Carlo (MCMC) with the
biased random walk Metropolis–Hastings algorithm [70, 71] was employed to approximate
the high-dimensional posterior distribution within the data to identify the optimal combinato-
rial glycan determinants that best fit the model predictions for binding with the experimental
data.
The model. We identified 110 sequons from the alignment of the 94 gp120 sequences uti-
lized for the Ab binding profiles. We hypothesized that each sequon could be classified as
either a “determinant” (critical for binding) or a “non-determinant” (not critical for binding)
for Ab binding. A determinant could either be an agonist or antagonist. The calculation to
identify glycan determinants was based on a joint probability distribution P(X) from a multi-
dimensional sequon space:
Joint probability ¼ PðXÞ;
X ¼ fx1; x2; :::::x110g
xi ¼
(
1 determinant
0 otherwise
ð2Þ
where the sequon index xi indicates a dimension, and contains two possible states [0, 1]. The
complete probability distribution containing 2110 states is overwhelming to exhaustive sam-
pling. Therefore, we used an approximation to provide a statistical estimate of the glycan deter-
minant distribution P(X) given a set of experimental observations. According to Bayes’
theorem, the conditional probabilities of the glycan determinants given an observed data set
are:
pðXoptjdataÞ ¼
pðdatajXoptÞpðXoptÞ
pðdataÞ
ð3Þ
where Xopt denotes the vector of the glycan determinants in the model and p(Xopt | data)
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represents the posterior of Xopt. p(data | Xopt) and p(Xopt) are likelihood and prior of Xopt,
respectively. Since the ratio of posterior is only required following MCMC sampling, the equa-
tion simplifies:
pðXoptjdataÞ / pðdatajXoptÞpðXoptÞ ð4Þ
Taking a log transformation then yields the sum of the log likelihood and the log prior:
  lnðposteriorðXoptÞÞ ¼
  lnðlikelihoodðXoptÞÞ   lnðpriorðXoptÞÞ
ð5Þ
–ln(likelihood(Xopt)) was calculated by mean squared errors (MSE) between the prediction
from SVR and the observed data. SVR was trained on a sub-set of glycan site occupancy pro-
files (Xopt), and examined by means of 10-fold cross-validation randomly dividing the data
into training and test sets with fitness estimated by calculating MSE. -ln(prior(Xopt)) was calcu-
lated by the sum of squared deviation between the selected and empirical glycan determinants,
assuming that the distribution of the site identified between two states [0, 1] follows a Gaussian
distribution:
  lnðpriorðXoptÞÞ ¼
X
j
1
2s2j
ðxj   hxjiÞ
2
ð6Þ
σ2j and<xj> are variance and mean of glycan occupancy at the site xj. To sample the desired
probability distribution P(X) we implemented a Metropolis–Hastings MCMC walk, in which
the algorithm iteratively computed the posterior at current and next position. With this poste-
rior assumed proportional to P(X), the decision of jumping to the next position was then
obtained:
Xsþ1 ¼
(X0 if Unif ð0; 1Þ  aðXs;X0Þ
Xs otherwise
aðXs;X0Þ ¼ min 1;
posteriorðX0Þ
posteriorðXsÞ
 
ð7Þ
Xs indicates the current position and X’ the candidate for the next position; Xs+1 the next posi-
tion. The distribution α of the next position depends only on the current position value, by
definition of the Markov chain. The algorithm accordingly generated a sequence of sample val-
ues in which the distribution of values closely approximated the original probability distribu-
tion P(X).
The calculation procedure started from a randomly selected set of glycan determinants and
performed 50,000 iterations of MCMC walk for each Ab, in order to converge on a desired dis-
tribution (Figure M in S1 File); the first 5,000 iterations were discarded as a burn-in period
which identified very different distributions. The output of this calculation provided marginal
probabilities for each sequon identified as a determinant (Figure N in S1 File). We performed
10 cycles of MCMC walk for each Ab to avoid the potential problem of the search getting
trapped in local optima. To estimate statistical significance among the sequons, a background
model was calculated in which the original glycan occupancy matrix was permuted by shuf-
fling the order of gp120 proteins to preserve the heterogeneity of glycan occupancy yet capture
noise effects. This background model was performed for each Ab using 100 permutations to
estimate null distribution for individual sequons, with the null hypothesis posed that the gly-
can at the site has no impact on the Ab binding. Only the sites whose q-value after multiple-
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testing adjustment showed statistical significance (q<0.01) (Figure F in S1 File), rejecting the
null hypothesis, were identified as glycan site “determinants”. We used a customized Matlab
script for Metropolis–Hastings MCMC algorithm, implemented Matlab LIBSVM package [82]
for SVR with SVR parameters, kernel type = linear, cost = 0.75, and the epsilon = 0.1. The algo-
rithm was run on Linux computing clusters.
To evaluate whether model balance between under- or over-fitting, a learning curve tech-
nique [83] was employed to calculate training error and cross-validation error as a function of
training set size.
EtrainðyÞ ¼
1
2N
XN
i¼1
ðJyðx
ðiÞÞ   yðiÞÞ2
EcvðyÞ ¼
1
2Ncv
XNcv
i¼1
ðJyðx
ðiÞ
cv Þ   y
ðiÞ
cv Þ
2
ð8Þ
where N indicates the training set size and Ncv the testing set size in cross-validation. Jθ(x)
denotes the regression function of SVR and y represents the actual Ab binding fingerprint. A
learning curve was used to evaluate the model fitting given the predictors (Figure O in S1 File).
An under-fitting model was recognized if only one glycan site occupancy profile was found as
a predictor, in which large training errors quickly emerged for a small training set (Figure O in
S1 File, the left panel). An over-fitting model was obtained if all glycan occupancy profiles
were found as predictors, in which the cross-validation errors decreased shortly but then grew
as the training set size increased further (Figure O in S1 File, the middle panel). A model using
the glycan site determinants identified from the Bayesian machine learning algorithm as the
predictors showed excellent fitting behavior, in which both the training and cross-validation
errors converged at the level of the expected errors from experimental noise (Figure O in S1
File, the right panel).
To determine how the glycan determinants modulate Ab recognition, the directional
weight (DW) was introduced and calculated:
DW ¼ pðxiÞ  d
d ¼
(
1 if corrðAby;GxiÞ > 0
  1 otherwise
ð9Þ
p(xi) denotes the probability of a sequon being a “determinant” which was obtained from the
MCMC-SVR model and d represents a direction [1, –1] determined by the covariance matrix
between individual glycan occupancy pattern versus the Ab fingerprint (Fig 2C).
Identifying amino acid positions critical for Ab binding by Bayesian
MCMC-SVR
Bayesian MCMC-SVR was then extended to identify protein residues critical for Ab binding. The
peptide sequences of 94 gp120 proteins were pre-processed to remove less informative positions.
Based on multiple sequence alignment, 534 aligned positions were identified across the 94 pro-
teins. Positions at which the residues were identical in all proteins or where more than 10% of the
proteins had unknown residues, denoted as gaps, were removed, leaving only 303 common posi-
tions. For importing these data into the model, the finalized sequence data was encoded as a
6,363–dimensional vector (303 positions × 21 amino acid types including the gap), where every
single residue of the 303 positions in each sequence was converted from a categorized amino acid
into a binary vector. Ultimately, three models—glycan alone, sequence alone, and both glycan
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and sequence—were constructed for each Ab to assess the model prediction performance as well
as identify the critical glycan site and protein residues that may tune Ab binding.
De Novo computational design for antigenically optimized antigens via
glycan-engineering
Using the Bayesian MCMC-SVR algorithm that identified the glycan determinants positively
or negatively impacting Ab binding, the data were further analyzed to rationally design anti-
gens with selective Ab antigenic-profiles. The same training set (glycan occupancy, Ab finger-
prints and envelope sequences) and model algorithm were utilized, but now modified to
search for global optimum solutions for best or worst binding (the objective function -ln(poste-
rior(Xopt)) is modified). Given a set of previously identified Ab-specific glycan determinant
sites denoted as X, the model in this section attempted to determine the likelihood of the pres-
ence or absence of each critical site associated with the optimized Ab binding:
Joint probability of the optimized binding ¼ PðXÞ
X ¼ fx1; x2; :::::xmg
xi ¼
(
1 Presence
0 Absence
ð10Þ
where each glycan determinant xi contained two states [0, 1]. Thus, the model aimed to
approximate the joint probability distribution P(X) by implementing the same Bayesian
MCMC sampling as earlier (Eq 5).–ln(posterior(Xopt)) represented the predicted antigenicity
from the trained SVR model given a set of combinatorial sites Xopt.
For sampling within the multi-dimensional probability distribution P(X), we performed
200,000 iterations to reach convergence from an initial gp120 sequence, and estimated the
global sequon occupancy profile for an antigen that yields optimized Ab binding. Each itera-
tion simulated the evolutionary process of mutagenesis, in which the state of a selected site xi
was altered between 0 and 1 analogous to random knockout/insertion of the sequon; an evolu-
tionary driving force is assumed to mainly depend on predicted antigenicity. Accordingly, in
each iteration determination was made of whether the sequon should be added or removed by
computing the ratio of posteriors for the current and previous iteration according to Eq 7; that
is, we computed the ratio of predicted antigenicity between current versus previous iterations.
The final output of the model was the marginal probabilities of two states at every glycan deter-
minant. High probability of state 1 suggested that the glycan determinant most likely facilitated
Ab binding, so that the sequon should be included in the optimal antigen design. Conversely,
high probability of state 0 suggested that occupancy at that sequon would impair Ab recogni-
tion, suggesting that this site should be excluded. Ultimately, the model was able to identify
optimized profiles of glycan determinants on the antigens with ideal antigenicity.
When generating a de novo peptide sequence from a gp120 sequence template to accommodate
an ideal glycan determinant profile, addition and deletion of sequons was accomplished according
to these rules: (1) if a sequon needed to be eliminated, a Asn-to-Gln substitution at the sequon was
introduced; (2) if a new sequon needed to be introduced, a N-L-T sequence was substituted into
the original sequence (although if multiple sequons were modeled that were in close proximity
[e.g., N187.6 and N187.7] only the first site would be added to avoid steric hindrance).
Incorporating steric effects of the glycans into gp120 antigen design
To incorporate the steric hindrance effects of proximal glycans, pairs that negatively impacted
one another were identified. Our hypothesis was that if two glycans sterically constrained each
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other, the glycan occupancy patterns should be mutually exclusive; i.e., they should have strong
negative correlation. Therefore, a covariance matrix was constructed containing all pairs of
glycan-glycan auto-correlations. To determine statistical significance, a nominal P-value of
each pair was calculated, assuming that the distribution of all pairs of correlation coefficients
followed a Gaussian process, and an adjusted p-value was corrected to account for multiple
hypothesis testing (False discovery rate adjusted p-value< 0.1). Glycan pairs with significant
mutual exclusion were then identified (Figure J in S1 File). Next, to estimate the total degree of
steric hindrance potentially induced on the epitope of the antigen, the mutually exclusive gly-
can pairs were taken into account. Each glycan pair possessed a steric hindrance weight based
on the glycan-glycan correlation coefficient, and total weights of the included glycan pairs
were summed up to represent total degree of steric hindrance. Mean and s.d. of the steric hin-
drance were estimated across all 94 gp120 proteins which represented the basal level of the ste-
ric hindrance occurring on naïve gp120 proteins. To incorporate the steric hindrance effects
on antigen design, the antigens, after de novo design, were then evaluated for total degree of
steric hindrance. Steric hindrance levels greater than the basal level (> mean + 1 s.d.) were
considered to be larger than acceptable. Glycan sites that showed the least effect on bNAb
binding from steric hindrance were removed one at a time until an acceptable level of steric
hindrance was achieved. The process of removing steric glycan sites was repeated until total
degree of steric hindrance was lower than mean+1 s.d.
Recombinant Env glycoprotein expression and purification
The sequence encoding wild-type MF535.W0M.ENV.D11 gp120 and PGT121+/-/PGT128+/-
optimized glycoproteins, including a signal peptide-‘MPMGSLQPLATLYLLGMLVASVLA’ at
N-terminus and an avitag-‘GLNDIFEAQKIEWHE’ followed by a histag-’HHHHHH’ at the C-
terminus, were synthesized and inserted into pcDNA3.1 (Thermo Fisher). Plasmid DNA was
purified and verified by sequencing. Plasmids encoding these proteins were transfected into
293-F cells (Life Technologies, cat. no. R790-07) and proteins were isolated from expression
supernatants 6 days after transfection. Briefly, gp120 proteins were purified by metal affinity
chromatography using Ni-NTA resin (Qiagen). Fractions containing gp120 were combined
and oligomers, trimers and monomers were separated by gel filtration chromatography using
a Hi-Load 16/60 Superdex 200pg column (GE Healthcare). Protein purity was confirmed by
SDS-PAGE gel electrophoresis and Western blotting using a mouse monoclonal Ab Chessie
13–39.1 (NIH, AIDS Reagents Program) (Figure H in S1 File).
Code availability
MATLAB source codes for the Bayesian MCMC-SVR algorithm to identify glycan/sequence
determinants, and the de novo antigen optimization design program, can be accessed from
Supplementary Information.
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